Clinical Trial Update: London's Exogenous Surfactant Study for COVID19 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of exogenous surfactant for ARDS in COVID-19 completed in London.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Exogenous Surfactant (surfactant)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: ARDS, Human, COVID-19 | Phase 1, Phase 2 | Status: COMPLETED